Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases

[1]  N. Selzner,et al.  Inhibition of the Fibrinogen‐Like Protein 2:FcγRIIB/RIII immunosuppressive pathway enhances antiviral T‐cell and B‐cell responses leading to clearance of lymphocytic choriomeningitis virus clone 13 , 2018, Immunology.

[2]  T. Velavan,et al.  Interferon-stimulated gene 20 kDa protein serum levels and clinical outcome of hepatitis B virus-related liver diseases , 2018, Oncotarget.

[3]  Kun Zhang,et al.  Increased expression of Fibrinogen-Like Protein 2 is associated with poor prognosis in patients with clear cell renal cell carcinoma , 2017, Scientific Reports.

[4]  Q. Ning,et al.  IL‐33 protects murine viral fulminant hepatitis by targeting coagulation hallmark protein FGL2/fibroleukin expression , 2017, Molecular immunology.

[5]  P. Kremsner,et al.  SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B , 2017, Oncotarget.

[6]  Xinguang Liu,et al.  Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation , 2016, Oncotarget.

[7]  Q. Ning,et al.  Adenovirus‐mediated artificial microRNA against human fibrinogen like protein 2 inhibits hepatocellular carcinoma growth , 2016, The journal of gene medicine.

[8]  Q. Ning,et al.  A disparate subset of double-negative T cells contributes to the outcome of murine fulminant viral hepatitis via effector molecule fibrinogen-like protein 2 , 2016, Immunologic research.

[9]  I. Cherny,et al.  The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development. , 2015, Thrombosis research.

[10]  Guohong Deng,et al.  C5aR, TNF-α, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis. , 2015, Journal of hepatology.

[11]  A. Bertoletti,et al.  Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections , 2015, Hepatology.

[12]  H. Zhou,et al.  Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma , 2014, Hepatology International.

[13]  Wei-feng Chen,et al.  Overexpression of fibrinogen-like protein 2 induces epithelial-to-mesenchymal transition and promotes tumor progression in colorectal carcinoma , 2014, Medical Oncology.

[14]  Gui‐qing Li,et al.  C5a/C5aR pathway is essential for the pathogenesis of murine viral fulminant hepatitis by way of potentiating Fgl2/fibroleukin expression , 2014, Hepatology.

[15]  T. Zhu,et al.  The role of soluble fibrinogen-like protein 2 in transplantation: protection or damage. , 2014, Transplantation.

[16]  Darrin Gao,et al.  Targeted Deletion of FGL2 Leads to Increased Early Viral Replication and Enhanced Adaptive Immunity in a Murine Model of Acute Viral Hepatitis Caused by LCMV WE , 2013, PloS one.

[17]  M. Levrero,et al.  Molecular Mechanisms of HBV-Associated Hepatocarcinogenesis , 2013, Seminars in Liver Disease.

[18]  M. Cybulsky,et al.  Characterization of fibrinogen-like protein 2 (FGL2): monomeric FGL2 has enhanced immunosuppressive activity in comparison to oligomeric FGL2. , 2013, The international journal of biochemistry & cell biology.

[19]  T. Zhu,et al.  Serum level of soluble fibrinogen-like protein 2 in renal allograft recipients with acute rejection: a preliminary study. , 2012, Transplantation proceedings.

[20]  Q. Ning,et al.  Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[21]  H. Zhuang,et al.  [Updates of EASL clinical practice guidelines: management of chronic hepatitis B virus infection]. , 2012, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[22]  V. T. Nguyen.  Hepatitis B Infection in Vietnam , 2012, Asia-Pacific journal of public health.

[23]  Y. Yılmaz,et al.  Plasma fibrinogen-like protein 2 levels in patients with non-alcoholic fatty liver disease. , 2011, Hepato-gastroenterology.

[24]  Yuzhang Wu,et al.  Programmed Death (PD)-1-Deficient Mice Are Extremely Sensitive to Murine Hepatitis Virus Strain-3 (MHV-3) Infection , 2011, PLoS pathogens.

[25]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[26]  K. Wong,et al.  The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection. , 2010, Journal of hepatology.

[27]  N. Selzner,et al.  The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection , 2010, Rambam Maimonides medical journal.

[28]  K. Wong,et al.  The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen‐like protein 2 contributes to the outcome of murine fulminant viral hepatitis , 2009, Hepatology.

[29]  Q. Ning,et al.  Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma. , 2008, World journal of gastroenterology.

[30]  G. Dore,et al.  An enormous hepatitis B virus‐related liver disease burden projected in Vietnam by 2025 , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[31]  Q. Ning,et al.  Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. , 2006, Human gene therapy.

[32]  E. Cholongitas,et al.  Systematic review: the model for end‐stage liver disease – should it replace Child‐Pugh's classification for assessing prognosis in cirrhosis? , 2005, Alimentary pharmacology & therapeutics.

[33]  Q. Ning,et al.  Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. , 2005, World journal of gastroenterology.

[34]  R. Goldin,et al.  Management of chronic hepatitis B virus infection , 2004 .

[35]  Q. Ning,et al.  The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. , 2003, The Journal of clinical investigation.

[36]  P. Marsden,et al.  Genomic characterization, localization, and functional expression of FGL2, the human gene encoding fibroleukin: a novel human procoagulant. , 2001, Genomics.

[37]  P. Marsden,et al.  Molecular and Functional Analysis of the Human Prothrombinase Gene (HFGL2) and Its Role in Viral Hepatitis , 2000, The American Journal of Pathology.

[38]  O. Rotstein,et al.  FGL2/fibroleukin mediates hepatic reperfusion injury by induction of sinusoidal endothelial cell and hepatocyte apoptosis in mice. , 2012, Journal of hepatology.

[39]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[40]  H. El‐Serag,et al.  Hepatocellular carcinoma. , 2011, The New England journal of medicine.

[41]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.